Posts tagged Aurinia
Leerink ups Aurinia price target to $14

Leerink raised its price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) to $14 from $10 after the company’s R&D day in New York last Friday. The stock closed at $6.15 on Oct. 20.

Read More
Aurinia plans single Phase 3 trial of voclosporin in LN

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) plans to initiate a single Phase 3 clinical trial (Aurora), with a design consistent with that of the continuing Aura-LV clinical trial of voclosporin for the treatment of lupus nephritis (LN).

Read More
Analysts raise Aurinia price targets

Analysts for H.C. Wainwright and Leerink raised their price targets for Aurinia Pharmaceuticals (NASDAQ:AUPH) after the company reviewed positive Phase 2b trial data for voclosporin in lupus nephritis (LN), which met its complete and partial remission (CR/PR) endpoints at 48 weeks.

Read More
Aurinia’s voclosporin meets 48-week remission endpoints

Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) Phase 2b AURA-LV study of voclosporin in lupus nephritis (LN) met its complete and partial remission (CR/PR) endpoints at 48 weeks.

Read More
Richard Glickman adds CEO title at Aurinia

Richard Glickman, founder and chairman of Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP), was named to the added post of CEO. The board also accepted the resignation of Charles Rowland as CEO and an executive member of the board, effective immediately.

Read More
Aurinia to begin Phase 3 voclosporin trial in Q2

After an end-of-Phase 2 meeting with the FDA, Aurinia Pharmaceuticals (NASDAQ:AUPH) plans to begin a single Phase 3 clinical trial for voclosporin in the treatment of lupus nephritis (LN).

Aurinia believes the Phase 3 trial, whose design is consistent with the ongoing AURA study, will support a NDA submission.

Read More
Mackie starts Aurinia Pharma at speculative buy

Mackie Research launched coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a “speculative buy” recommendation and a 12-month target price of $8. The stock closed at $3.03 on Monday.

Aurinia is developing voclosporin as a first-line treatment for lupus nephritis (LN) and advancing the drug candidate into Phase 3 trials.

Read More
Leerink reiterates outperform rating on Aurinia post-data

Leerink reiterated its “outperform” rating on Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) after the company reported additional positive data for its voclosporin drug candidate in patients with active lupus nephritis.

Analyst Joseph Schwartz writes that data presented today at the European Lupus Meeting showed that 70% of patients (seven-of-10) achieved complete remission (CR) at 24 weeks, compared with 57% (four-of-seven patients) reported in July.

Read More
Aurinia posts positive Phase 2b voclosporin results

Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) voclosporin achieved its primary endpoint of complete remission (CR) at 24 weeks in a Phase 2b trial.

In addition, when both doses of voclosporin were added to the current standard of care of mycophenolate mofetil and a forced oral corticosteroid taper, voclosporin met all 24-week prespecified secondary endpoints versus the control group.

Read More